Plain-English translation of NCT03368651 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a treatment called transarterial chemoinfusion (TAI) — a way of delivering chemotherapy directly to the liver through a thin tube — can help patients with liver cancer live longer when given before surgery. Half of the patients will receive this pre-surgery treatment followed by an operation to remove the cancer, while the other half will go straight to surgery without the chemotherapy first. Researchers want to see if the medication helps improve survival.
Liver cancer that has spread into the major blood vessels of the liver is very difficult to treat and usually has poor outcomes. This trial exists to find out whether giving this treatment before surgery can help destroy more cancer cells and give patients a better chance of survival.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will receive the chemotherapy infusion treatment before surgery, while the other group will go straight to surgery. Either way, you will have the cancer removed surgically. You'll have regular blood tests and imaging scans to monitor your health, and the researchers will follow you over time to see how well you recover and how long you survive. The trial is recruiting 230 patients total across the study sites.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China